Literature DB >> 19691480

Low protein C and incidence of ischemic stroke and coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.

A R Folsom1, T Ohira, K Yamagishi, M Cushman.   

Abstract

BACKGROUND: Protein C is an important plasma natural anticoagulant. Although protein C deficiency increases risk of venous thrombosis, it remains uncertain whether low protein C increases risk of atherothrombosis.
OBJECTIVE: To examine whether low protein C may be a risk factor for ischemic stroke or coronary events in a prospective population-based study. PATIENTS/
METHODS: The Atherosclerosis Risk in Communities Study assessed protein C antigen by ELISA at baseline in 1987-89 and followed participants (n = 13 879) for incident ischemic stroke or coronary events through 2005.
RESULTS: Over a median of 16.9 years of follow-up, 613 ischemic strokes and 1257 coronary heart disease events occurred. Protein C was inversely associated with incidence of ischemic stroke. Adjusted for multiple risk factors, the rate ratios (95% CIs) from highest to lowest quintiles were 1.0, 1.16 (0.90-1.50), 1.22 (0.94-1.58), 1.18 (0.90-1.55) and 1.52 (1.17-1.98). This inverse association was stronger for non-lacunar and cardioembolic stroke than for lacunar stroke. In contrast, there was a positive association between protein C and coronary heart disease in incompletely adjusted models, but no association after adjustment for plasma lipids.
CONCLUSIONS: In this cohort study, low protein C was a risk factor for incident ischemic stroke but not coronary heart disease. Levels of protein C associated with stroke risk were not restricted to the traditional 'deficient' range for protein C (< 0.5 percentile), suggesting that other etiologies for a lower protein C, or genetic variants associated with more subtle changes in protein C, are playing a role in disease pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19691480      PMCID: PMC2819378          DOI: 10.1111/j.1538-7836.2009.03577.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  17 in total

1.  Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.

Authors:  A R Folsom; W D Rosamond; E Shahar; L S Cooper; N Aleksic; F J Nieto; M L Rasmussen; K K Wu
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

Review 2.  Inherited thrombophilia: Part 1.

Authors:  D A Lane; P M Mannucci; K A Bauer; R M Bertina; N P Bochkov; V Boulyjenkov; M Chandy; B Dahlbäck; E K Ginter; J P Miletich; F R Rosendaal; U Seligsohn
Journal:  Thromb Haemost       Date:  1996-11       Impact factor: 5.249

3.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

4.  Community surveillance of coronary heart disease in the Atherosclerosis Risk in Communities (ARIC) Study: methods and initial two years' experience.

Authors:  A D White; A R Folsom; L E Chambless; A R Sharret; K Yang; D Conwill; M Higgins; O D Williams; H A Tyroler
Journal:  J Clin Epidemiol       Date:  1996-02       Impact factor: 6.437

5.  Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.

Authors:  W D Rosamond; A R Folsom; L E Chambless; C H Wang; P G McGovern; G Howard; L S Copper; E Shahar
Journal:  Stroke       Date:  1999-04       Impact factor: 7.914

6.  Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  A R Folsom; K K Wu; W D Rosamond; A R Sharrett; L E Chambless
Journal:  Circulation       Date:  1997-08-19       Impact factor: 29.690

7.  Absence of thrombosis in subjects with heterozygous protein C deficiency.

Authors:  J Miletich; L Sherman; G Broze
Journal:  N Engl J Med       Date:  1987-10-15       Impact factor: 91.245

8.  Short-term intraindividual variability in hemostasis factors. The ARIC Study. Atherosclerosis Risk in Communities Intraindividual Variability Study.

Authors:  L E Chambless; R McMahon; K Wu; A Folsom; A Finch; Y L Shen
Journal:  Ann Epidemiol       Date:  1992-09       Impact factor: 3.797

9.  ARIC hemostasis study--I. Development of a blood collection and processing system suitable for multicenter hemostatic studies.

Authors:  A C Papp; H Hatzakis; A Bracey; K K Wu
Journal:  Thromb Haemost       Date:  1989-02-28       Impact factor: 5.249

10.  Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study)

Authors:  T Koster; F R Rosendaal; E Briët; F J van der Meer; L P Colly; P H Trienekens; S R Poort; P H Reitsma; J P Vandenbroucke
Journal:  Blood       Date:  1995-05-15       Impact factor: 22.113

View more
  19 in total

1.  Identification of Genetic Variants Linking Protein C and Lipoprotein Metabolism: The ARIC Study (Atherosclerosis Risk in Communities).

Authors:  James S Pankow; Weihong Tang; Nathan Pankratz; Weihua Guan; Lu-Chen Weng; Mary Cushman; Eric Boerwinkle; Aaron R Folsom
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-12       Impact factor: 8.311

2.  Hemostasis biomarkers and incident cognitive impairment: the REGARDS study.

Authors:  S R Gillett; L A McClure; P W Callas; E L Thacker; F W Unverzagt; V G Wadley; A J Letter; M Cushman
Journal:  J Thromb Haemost       Date:  2018-06-06       Impact factor: 5.824

Review 3.  Activated protein C in neuroprotection and malaria.

Authors:  Laurent O Mosnier
Journal:  Curr Opin Hematol       Date:  2019-09       Impact factor: 3.284

4.  Hemostatic Factors, APOL1, and ESRD Risk: Another Piece of the Puzzle?

Authors:  Walter G Wasser; Etty Kruzel-Davila
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

Review 5.  Cytoprotective-selective activated protein C therapy for ischaemic stroke.

Authors:  Laurent O Mosnier; Berislav V Zlokovic; John H Griffin
Journal:  Thromb Haemost       Date:  2014-09-18       Impact factor: 5.249

6.  Hemostatic markers are associated with the risk and prognosis of atrial fibrillation: the ARIC study.

Authors:  Alvaro Alonso; Weihong Tang; Sunil K Agarwal; Elsayed Z Soliman; Alanna M Chamberlain; Aaron R Folsom
Journal:  Int J Cardiol       Date:  2010-10-20       Impact factor: 4.164

7.  Hemostatic Factors, APOL1 Risk Variants, and the Risk of ESRD in the Atherosclerosis Risk in Communities Study.

Authors:  Adrienne Tin; Morgan E Grams; Nisa M Maruthur; Brad C Astor; David Couper; Thomas H Mosley; Myriam Fornage; Rulan S Parekh; Josef Coresh; Wen Hong Linda Kao
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-17       Impact factor: 8.237

8.  Limited ability to activate protein C confers left atrial endocardium a thrombogenic phenotype: a role in cardioembolic stroke?

Authors:  Jorge Cerveró; Ramón Montes; Francisco España; Charles T Esmon; José Hermida
Journal:  Stroke       Date:  2011-06-23       Impact factor: 7.914

9.  Clinical Impact of Thrombophilia Screening in Young Adults with Ischemic Stroke.

Authors:  Setareh S Omran; Michael P Lerario; Gino Gialdini; Alexander E Merkler; Antonio Moya; Monica L Chen; Hooman Kamel; Maria DeSancho; Babak B Navi
Journal:  J Stroke Cerebrovasc Dis       Date:  2018-12-27       Impact factor: 2.136

10.  Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS).

Authors:  Neil A Zakai; Suzanne E Judd; Brett Kissela; George Howard; Monika M Safford; Mary Cushman
Journal:  Thromb Haemost       Date:  2018-06-11       Impact factor: 5.249

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.